Reaction

Blood Loss Anaemia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,202 reports · 85 co-occurring drugs

As of the last recalculation, Blood Loss Anaemia appears in 2,202 FAERS reports alongside 85 co-occurring drug terms. The strongest observed disproportionality signal is RIVAROXABAN (PRR 25.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Rivaroxaban	449	25.4	25.4
Dabigatran Etexilate	181	23.9	24.0
Dabigatran Etexilate Mesylate	168	23.6	23.6
Clopidogrel Bisulfate	187	18.8	18.8
Dronedarone	18	16.8	16.8
Metolazone	19	16.1	16.1
Heparin Sodium	21	14.6	14.6
Torsemide	49	14.3	14.3
Ferrous Sulfate	72	14.0	14.0
Apixaban	81	11.8	11.9
Enoxaparin Sodium	68	11.5	11.5
Clopidogrel	216	11.3	11.3
Ursosiol	23	11.3	11.3
Sucralfate Oral	16	10.7	10.7
Sucralfate Oral Suspension	16	10.7	10.7
Desloratadine	12	10.6	10.6
Ticagrelor	35	10.5	10.5
Ketoprofen	14	10.1	10.2
Ursodiol	23	10.1	10.1
Sucralfate	24	9.6	9.6
Candesartan	35	9.4	9.4
0Xygen	46	9.0	9.0
Oxygen	46	9.0	9.0
Eplerenone	12	8.9	8.9
Terazosin Hydrochloride	8	8.5	8.5
Tranexamic Acid	8	8.5	8.5
Vibegron	7	8.3	8.3
Polyethylene Glycol	9	7.9	7.9
Remdesivir	11	7.8	7.8
Potassium Chloride	91	7.8	7.8
Psyllium Husk	8	7.7	7.7
Macitentan	55	7.7	7.7
Potassium Chloride, Dextrose Monohydrate	73	7.7	7.7
Potassium Chloride Oral	73	7.7	7.7
Potassium Chloride Extended-Release	73	7.7	7.7
Nitroglycerin	42	7.5	7.5
Riociguat	25	7.3	7.3
Cefazolin	7	7.3	7.3
Furosemide	275	7.3	7.3
Dalteparin Sodium	8	7.2	7.2
Carvedilol	98	7.1	7.1
Alteplase	11	7.0	7.0
Aspirin	341	6.9	6.9
Sotalol Hydrochloride	12	6.9	6.9
Misoprostol	7	6.8	6.8
Selexipag	18	6.6	6.6
Bisoprolol Fumarate	90	6.5	6.5
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	14	6.5	6.5
Metoprolol Succinate	58	6.5	6.5
Naproxen Sodium, Pseudoephedrine Hydrochloride	14	6.5	6.5
Etonogestrel	32	6.4	6.4
Warfarin Sodium	31	6.4	6.4
Cefazolin Sodium	8	6.3	6.3
Trifluridine And Tipiracil	7	6.2	6.2
Bumetanide	17	6.1	6.1
Isosorbide Mononitrate	13	6.0	6.0
Inclisiran	5	5.9	5.9
Baricitinib	6	5.9	5.9
Dutasteride	5	5.8	5.8
Dextrose	8	5.8	5.8
Regorafenib	7	5.7	5.7
Dextrose Monohydrate	8	5.7	5.7
Romiplostim	9	5.7	5.7
Sildenafil	34	5.6	5.6
Ado-Trastuzumab Emtansine	5	5.6	5.6
Guaifenesin	18	5.6	5.6
Hydroxyurea	12	5.4	5.4
Brimonidine Tartrate	10	5.3	5.3
Oxazepam	12	5.3	5.3
Dapagliflozin	17	5.1	5.1
Encorafenib	5	4.8	4.8
Fondaparinux Sodium	4	4.7	4.7
Tadalafil	48	4.6	4.6
Emicizumab	6	4.6	4.6
Dofetilide	5	4.5	4.5
Miconazole Nitrate	4	4.3	4.3
Tiotropium Bromide Inhalation Spray	5	4.2	4.2
Sevelamer Carbonate	5	4.1	4.1
Polatuzumab Vedotin	4	3.9	3.9
Treprostinil	50	3.8	3.8
Romosozumab-Aqqg	5	3.5	3.5
Tapentadol Hydrochloride	10	2.8	2.8
Levonorgestrel	53	2.5	2.5
Patiromer	3	2.1	2.1
Copper	5	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.